Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience

[1]  G. Johannsson.  Improving glucocorticoid replacement in patients with adrenal insufficiency , 2016, Endocrine.

[2]  C. Comiter,et al.  Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder , 2016, Neurourology and urodynamics.

[3]  Stefan R Bornstein,et al.  Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[4]  N. Martin,et al.  Clinical outcomes in patients with nonfunctioning pituitary adenomas managed conservatively , 2015, Clinical endocrinology.

[5]  P. Chanson,et al.  Management of nonfunctioning pituitary incidentaloma. , 2015, Annales d'endocrinologie.

[6]  A. Wierinckx,et al.  Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. , 2015, European journal of endocrinology.

[7]  P. Beck‐Peccoz,et al.  Hypothalamic-Pituitary Axis in Non-Functioning Pituitary Adenomas: Focus on the Prevalence of Isolated Central Hypoadrenalism , 2015, Neuroendocrinology.

[8]  C. Yedinak,et al.  Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study , 2015, Pituitary.

[9]  Joseph M Pappachan,et al.  Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. , 2015, The Journal of clinical endocrinology and metabolism.

[10]  A. Tirosh,et al.  Hypopituitarism patterns and prevalence among men with macroprolactinomas , 2015, Pituitary.

[11]  R. Salvatori.  Surgical treatment of microprolactinomas: pros , 2014, Endocrine.

[12]  C. Benbassat,et al.  Clinical course and outcome of nonfunctioning pituitary adenomas in the elderly compared with younger age groups. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[13]  N. Karavitaki,et al.  Does hypopituitarism recover when macroprolactinomas are treated with cabergoline? , 2013, Clinical endocrinology.

[14]  P. Dahlqvist,et al.  Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. , 2013, The Journal of clinical endocrinology and metabolism.

[15]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[16]  D. Greenwood,et al.  Meta-analysis of Observational Studies , 2012 .

[17]  N. Karavitaki,et al.  The postoperative monitoring of nonfunctioning pituitary adenomas , 2011, Nature Reviews Endocrinology.

[18]  V. Montori,et al.  Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. , 2011, The Journal of clinical endocrinology and metabolism.

[19]  Victor M Montori,et al.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[20]  M. Molitch,et al.  Chapter 15 – Prolactinoma , 2011 .

[21]  K. Mann,et al.  Recovery of pituitary function in the late-postoperative phase after pituitary surgery: results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgery. , 2010, European journal of endocrinology.

[22]  A. Klibanski,et al.  Clinical practice. Prolactinomas. , 2010, The New England journal of medicine.

[23]  Alberto Fernández,et al.  Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK) , 2010, Clinical endocrinology.

[24]  W. Ludlam.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK) , 2010 .

[25]  Joshua R. Dusick,et al.  Pituitary Hormonal Loss and Recovery After Transsphenoidal Adenoma Removal. , 2010, Neurosurgery.

[26]  C. Yedinak,et al.  Normal hypothalamic-pituitary-adrenal axis by high-dose cosyntropin testing in patients with abnormal response to low-dose cosyntropin stimulation: a retrospective review. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[27]  F. Greenway,et al.  An Endocrine Society Clinical Practice Guideline Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: , 2010 .

[28]  R. Clayton,et al.  ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.

[29]  A. Colao.  Pituitary tumours: the prolactinoma. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[30]  Steven D Chang,et al.  Non-surgical management of hormone-secreting pituitary tumors , 2009, Journal of Clinical Neuroscience.

[31]  M. Maghnie,et al.  Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis. , 2008, The Journal of clinical endocrinology and metabolism.

[32]  D. McArthur,et al.  PITUITARY HORMONAL LOSS AND RECOVERY AFTER TRANSSPHENOIDAL ADENOMA REMOVAL , 2008, Neurosurgery.

[33]  O. Dekkers,et al.  Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. , 2008, The Journal of clinical endocrinology and metabolism.

[34]  A. Colao,et al.  Advances in the treatment of prolactinomas. , 2006, Endocrine reviews.

[35]  A. Beckers,et al.  The Epidemiology of Prolactinomas , 2017, Pituitary.

[36]  G. Stalldecker,et al.  Retrospective Multicentric Study of Pituitary Incidentalomas , 2005, Pituitary.

[37]  Shereen Ezzat,et al.  The prevalence of pituitary adenomas , 2004, Cancer.

[38]  R. Kristof,et al.  Non-functioning pituitary adenomas: endocrinological and clinical outcome after transsphenoidal and transcranial surgery. , 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[39]  P. Cappabianca,et al.  Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. , 2004, The Journal of clinical endocrinology and metabolism.

[40]  R. Quinton,et al.  Medical Therapy of Macroprolactinomas in Males: I. Prevalence of Hypopituitarism at Diagnosis. II. Proportion of Cases Exhibiting Recovery of Pituitary Function , 2001, Pituitary.

[41]  A. Klibanski,et al.  Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. , 2003, The Journal of clinical endocrinology and metabolism.

[42]  P. Cappabianca,et al.  Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. , 2003, European journal of endocrinology.

[43]  W. Selman,et al.  The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. , 2000, The Journal of clinical endocrinology and metabolism.

[44]  M. Rigla,et al.  Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. , 1999, The Journal of clinical endocrinology and metabolism.

[45]  K. Kurisu,et al.  Anterior pituitary function in patients with nonfunctioning pituitary adenoma: results of longitudinal follow-up. , 1995, Endocrine journal.

[46]  B. Corenblum,et al.  The natural history of the pituitary incidentaloma. , 1995, Archives of internal medicine.

[47]  B. Arafah,et al.  Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. , 1986, The Journal of clinical endocrinology and metabolism.

[48]  M. Molitch,et al.  Bromocriptine as Primary Therapy for Prolactin-Secreting Macroadenomas: Results of a Prospective Multicenter Study* , 1985 .

[49]  M. Molitch,et al.  Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. , 1985, The Journal of clinical endocrinology and metabolism.

[50]  P. Snyder,et al.  Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function. , 1984, Annals of Internal Medicine.

[51]  D. Becker,et al.  Residual anterior pituitary function following transsphenoidal resection of pituitary macroadenomas. , 1984, Journal of neurosurgery.

[52]  R. Firth.  Function , 1955, Yearbook of Anthropology.

[53]  Henry Southern,et al.  The retrospective review , 1820 .